NEWS
View news from our Featured Companies.
ContraPest® Success Stories Reported at Vertebrate Pest Conference
PHOENIX, Feb. 28, 2023 -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced that...
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) ("the Company"), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 8, 2023 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and...
IRADIMED CORPORATION Issues Urgent Medical Device Correction
Letter Notifying Customers of Potential Issues with MRidium 1057 MRI Syringe Adapter SetWINTER SPRINGS, Fla., Feb. 24, 2023 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) issued an Urgent Medical Device Correction Letter to notify affected customers of a...
Shuttle Pharmaceuticals Expands Laboratory Space to Advance Drug Development Pipeline and Diagnostic Capabilities
ROCKVILLE, Md., Feb. 23, 2023 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has...
ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space
Preclinical research suggests that NRH may be among the most potent and efficient of NAD+ precursors, and shows promise as a new therapeutic approach to ameliorating age-related NAD+ decline LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company...
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2022
PORTLAND, Maine, Feb. 21, 2023 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy...
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023
Second Consecutive Quarter of Positive Adjusted EBITDAQuarterly Net Revenue of $26.3 Million Driven by 23% Growth in Rx SegmentCompany to Host Conference Call Today at 5:00pm ETENGLEWOOD, CO / February 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu")...
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023
ENGLEWOOD, CO / February 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report...
A Letter from the ChromaDex Chief Executive Officer
LOS ANGELES - The following is issued on behalf of ChromaDex (NASDAQ: CDXC). Dear Fellow Shareholders: I want to take this opportunity to provide an update on ChromaDex's intellectual property portfolio, as well as perspective on why our business is not impacted by a...
SenesTech Names Nicole Williams as Chief Revenue Officer
PHOENIX, Feb. 16, 2023 -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today reported the...
ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022
Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ETPORTLAND, Maine, Feb. 15, 2023 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven...
LiqTech Enters Distribution Agreement with Liquinex in Singapore
BALLERUP, Denmark and SINGAPORE, Feb. 15, 2023 -- LiqTech International, Inc. (NASDAQ: LIQT), a clean technology company that manufactures and markets highly specialized filtration products and systems, and Liquinex, a Singapore-based specialist in water and...
Precision Optics Reports Second Quarter Fiscal Year 2023 Financial Results
Conference Call Scheduled for today, February 14, 2023 at 5:00pm ET GARDNER, Mass., Feb. 14, 2023 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries,...
Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results
ENGLEWOOD, CO / February 14, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, has announced the...
Precision Optics Enters into Production and Technology Licensing Agreement for Single-Use Ophthalmic Program
GARDNER, Mass., Feb. 13, 2023 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced it has signed a production and technology license agreement...
S&W Announces Second Quarter Fiscal 2023 Financial Results
LONGMONT, Colo., Feb. 13, 2023 -- S&W Seed Company (Nasdaq: SANW) today announced financial results for the three months ended December 31, 2022. Q2 2023 Financial and Recent Highlights Revenue for the second quarter of fiscal 2023 was $12.9 million, an increase...
Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023
PONTE VEDRA, Fla., Feb. 8, 2023 -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today announced that Chairman and...
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Following Positive Communication with the FDA, Regulatory Pathway Clarified for D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections Company Expects to Resume Patient Recruitment in Q2 2023 into Ongoing SHIELD II Trial, which will be Enriched with...
Precision Optics Corporation Schedules Second Quarter of Fiscal Year 2023 Conference Call for Tuesday, February 14, 2023
GARDNER, Mass., Feb. 7, 2023 -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced that it has scheduled a conference call to...
Shell and S&W Enter Joint Venture to Develop and Produce Sustainable Biofuel Feedstocks
LONGMONT, Colo. and HOUSTON, Feb. 7, 2023 -- Equilon Enterprises LLC ("Shell") and S&W Seed Company (Nasdaq: SANW) ("S&W"), a global agricultural company, today announced the execution of an agreement to establish a joint venture (the "JV") for the purpose of...
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023
ENGLEWOOD, CO / February 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report...
Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases
Encinitas, California--(February 7, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced it has received investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of the Ocular Presentation...
S&W Seed Company to Report Second Quarter Fiscal Year 2023 Financial Results on Monday, February 13, 2023
Conference call to be conducted on Monday, February 13, 2023, at 11:00AM ET LONGMONT, Colo., Feb. 6, 2023 -- S&W Seed Company (Nasdaq: SANW) will report financial results for its second quarter fiscal year 2023, ended December 31, 2022, on Monday, February 13,...
Cadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor Conference
PONTE VEDRA, Fla., Feb. 6, 2023 -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today announced that Chairman and...
ARIANNE EXTENDS WARRANT TERMS
DAN: TSX-V (Canada) JE9N: FSE (Germany) DRRSF: OTC (USA) SAGUENAY, QC, Feb. 3, 2023 /CNW Telbec/ - Arianne Phosphate (the "Company" or "Arianne") (TSXV: DAN) (OTC: DRRSF) (FRANKFURT: JE9N), a development-stage phosphate mining company, advancing the Lac à Paul...